Assorted news from the last week: Late Effects Surveillance System-Study Scan is an online publication that follows survivorship issues.  Click here for the latest edition, which includes several abstracts from late-effects research studies. New Research about Ewing Sarcoma: Researchers have discovered a gene, OTUD7A, that impacts the development of Ewing sarcoma, a bone cancer that occurs mainly in children. They have also identified a compound that shows potential to block OTUD7A protein activity. A new discovery in Ewing sarcoma has uncovered the potential to prevent cancer cells from spreading beyond their primary tumor site. Researchers have learned that Ewing sarcoma [...] Read more

Assorted news from the last week: FDA issues its final guidance on the RACE Act and specifies when sponsors must conduct pediatric studies for new cancer drugs as well as when those requirements can be waived or deferred. CAC2 Supporting Organization Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, went public and announced the pricing of its initial public offering of 10,000,000 shares of its common stock. Findings from an analysis of patients’ cognitive functioning after treatment of specific extracranial solid tumors [...] Read more

Assorted news from the last week: Thanks to a funding partnership among CAC2 Members, Spada Pediatric Sarcoma Foundation and Sam Day Foundation created theEwing Sarcoma Research Fund with a starting corpus of $250,000 within the Beat Childhood Cancer Research Consortium.  This fund will help drive genomic sequencing for kids battling Ewing sarcoma, using whole exome sequencing to look at both DNA and RNA to discover tumor pathways and targets with a goal of developing new clinical trials. Children who have blood cancers are less likely to survive after #BMT if their families are low-income compared to children from higher-income families, a [...] Read more

Assorted news from the last week: Survivors of childhood cancers are at increased risk for prescription opioid misuse compared with their peers, a review of a claims database revealed. A panel of pediatric cancer specialists endorsed the first-ever consensus recommendations for end-of-life care for children with cancer and their families. Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma Auburn men’s basketball coach Bruce Pearl and Florida football coach Dan Mullen were among the personalities on hand Friday night in Sarasota, Florida to help ESPN college basketball analyst Dick Vitale raise $5 million at a gala to support pediatric cancer […]

Read more

Assorted news from the last week: Thanks to a funding partnership among CAC2 Members, Spada Pediatric Sarcoma Foundation and Sam Day Foundation created the Ewing Sarcoma Research Fund with a starting corpus of $250,000 within the Beat Childhood Cancer Research Consortium. Cicadas and Chemo-Induced Hearing Loss Pediatric Cancer Research Foundation joins Oncoheroes Biosciences on their unique approach to defeat childhood cancer. For children with acute lymphoblastic leukemia (ALL), the type/dose of steroid seems not to be related to adverse psychological reactions (APRs) but may be associated with sleep problems, according to a review published in Psycho-Oncology. AstraZeneca and MSD’s selumetinib has [...] Read more